c-MET Protein (AA 25-932) (His tag)

Catalog No. ABIN2180660

Product Details

Target: c-MET (MET) (Met Proto-Oncogene (MET))

Protein Type: Recombinant

Biological Activity: Active

Protein Characteristics: AA 25-932

Origin: Human

Source: HEK-293 Cells

Purification tag / Conjugate: This c-MET protein is labelled with His tag.

Sequence: AA 25-932

Characteristics: rhHGFR is fused with a polyhistidine tag at the C-terminal. The mature form of HGFR is a disulfide-linked heterodimer composed of proteolytically cleaved α and β chain. Each α and β chain has a calculated MW of 32.5 kDa (α chain) and 60 kDa (β chain). The predicted N-terminal is Glu25 (α chain) & Ser308 (β chain). Protein migrates as 45 kDa (α chain) and 85-90 kDa (β chain) in reduced SDS-PAGE resulting from glycosylation.

Purity: >92 % as determined by SDS-PAGE.

Sterility: 0.22 μm filtered

Endotoxin Level: Less than 1.0 EU per μg by the LAL method.

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Buffer: PBS, pH 7.4

Handling Advice: Please avoid repeated freeze-thaw cycles.

Storage: -20 °C

Storage Comment: No activity loss was observed after storage at: In lyophilized state for 1 year (4 °C-8 °C), After reconstitution under sterile conditions for 1 month (4 °C-8 °C) or 3 months (-20 °C to -70 °C).

Target Details

Target: c-MET (MET) (Met Proto-Oncogene (MET))

Alternative Name: HGF R (MET Products)

Synonyms: AUTS9 Protein, HGFR Protein, RCCP2 Protein, c-Met Protein, AI838057 Protein, HGF Protein, Par4 Protein, Hgfr Protein, c-met Protein, MET Protein, C-MET Protein, met Protein, met-A Protein, MET proto-oncogene, receptor tyrosine kinase Protein, met proto-oncogene Protein, MET proto-oncogene, receptor tyrosine kinase L homeolog Protein, MET Protein, Met Protein, met.L Protein

Background: Hepatocyte growth factor receptor (HGFR) is also known as mesenchymal-epithelial transition factor (MET), c-Met, and is a glycosylated receptor tyrosine kinase that plays a central role in epithelial morphogenesis and cancer development. HGFR protein possesses tyrosine-kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. HGFR is normally expressed by cells of epithelial origin, while expression of HGF is restricted to cells of mesenchymal origin. Upon HGF stimulation, HGFR induces several biological responses that collectively give rise to a program known as invasive growth. Abnormal HGFR activation in cancer correlates with poor prognosis, where aberrantly active HGFR triggers tumor growth, formation of new blood vessels (angiogenesis) that supply the tumor with nutrients, and cancer spread to other organs (metastasis). HGFR is deregulated in many types of human malignancies, including cancers of kidney, liver, stomach, breast, and brain. Normally, only stem cells and progenitor cells express HGFR, However, cancer stem cells are thought to hijack the ability of normal stem cells to express HGFR, and thus become the cause of cancer persistence and spread to other sites in the body. Various mutations in the HGFR gene are associated with papillary renal carcinoma. HGFR mediates a complex program known as invasive growth. Activation of HGFR triggers mitogenesis, and morphogenesis.

Molecular Weight: 102.7 kDa

Pathways: RTK Signaling, Carbohydrate Homeostasis, Synaptic Membrane, Signaling of Hepatocyte Growth Factor Receptor